Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu • (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.
The drug targets enzymes that control the immune response and spleen macrophages.
Two new studies will have an intriguing mix of catalysts, “tunable” chemical bonds, supercomputers and ultrafast lasers.
A gene mutation causes wrinkled skin and hair loss; turning off that mutation restores the mouse to normal appearance.
The mechanism the tuberculosis pathogen uses in its escape suggests possible therapies to improve patient outcomes.
A gene called TXNIP was the answer, and it led to a drug called verapamil and a successful diabetes trial.
A diabetes drug suggests potential therapy for idiopathic pulmonary fibrosis, based on research with human lung fibroblasts and a mouse model of lung fibrosis.
These immune cells could become therapeutic targets to treat Crohn’s disease and ulcerative colitis.
The dying cells send signals to recipient tumor cells to increase aggressiveness, motility, and resistance to radiation or chemotherapy.
Two Novel Research grants from the Lupus Research Alliance boost the study of this complex disease.
Such analysis, researchers say, can help identify pathogen contact points between species, including pathogens causing human disease.